BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Tyagi N. Prevalence of Bloodstream Infections and their Etiology in COVID-19 Patients: A Tale of Two Cities. Indian J Crit Care Med 2021;25:355-7. [PMID: 34045795 DOI: 10.5005/jp-journals-10071-23797] [Reference Citation Analysis]
2 Behal M, Barlow B, Mefford B, Thompson Bastin ML, Donaldson JC, Laine M, Bissell BD. Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. Crit Care Explor 2021;3:e0492. [PMID: 34278319 DOI: 10.1097/CCE.0000000000000492] [Reference Citation Analysis]
3 Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Martín-García E, Nebot P, de la Torre R, Gurt A, Maldonado R, Monfort J; Covidmar Study Group. COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments. Front Pharmacol 2020;11:583260. [PMID: 33519443 DOI: 10.3389/fphar.2020.583260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Martin C, Muls V, Brasseur C, Meric de Bellefon L, Lam Hoai XL, Vanderhilst J, Delforge M, Di Romana S. ImmunoStart: preparing patients for immunosuppression. Rheumatol Adv Pract 2021;5:rkab092. [PMID: 34909567 DOI: 10.1093/rap/rkab092] [Reference Citation Analysis]
5 Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, Perricone R, Gerli R. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020;111:102468. [PMID: 32317220 DOI: 10.1016/j.jaut.2020.102468] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 30.5] [Reference Citation Analysis]
6 Bjornsson AH, Palsson O, Kristjansson M, Gunnarsson PS, Grondal G, Gudbjornsson B, Love TJ; ICEBIO. Outpatient Use of Antimicrobials in Patients With Rheumatoid Arthritis Before and After Treatment With Tumor Necrosis Factor Inhibitors: A Nationwide Retrospective Cohort Study. ACR Open Rheumatol 2021. [PMID: 34842362 DOI: 10.1002/acr2.11382] [Reference Citation Analysis]
7 Guo Y, Hu K, Li Y, Lu C, Ling K, Cai C, Wang W, Ye D. Targeting TNF-α for COVID-19: Recent Advanced and Controversies. Front Public Health 2022;10:833967. [DOI: 10.3389/fpubh.2022.833967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Serling-Boyd N, Mohareb AM, Kim AY, Hyle EP, Wallace ZS. The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. Ann Rheum Dis. 2021;80:274-276. [PMID: 32732241 DOI: 10.1136/annrheumdis-2020-218289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int 2021;21:614. [PMID: 34809619 DOI: 10.1186/s12935-021-02325-9] [Reference Citation Analysis]
10 Dias VL, Storrer KM. Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression. J Bras Pneumol 2022;48:e20210382. [PMID: 35352793 DOI: 10.36416/1806-3756/e20210382] [Reference Citation Analysis]
11 Zhai R, Ge X, Li H, Tang Z, Liao R, Kleinjans J. Differences in cellular and inflammatory cytokine profiles in the bronchoalveolar lavage fluid in bagassosis and silicosis. Am J Ind Med 2004;46:338-44. [PMID: 15376226 DOI: 10.1002/ajim.20051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]